The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A prognostic gene-signature based identification of high-risk thin melanomas.
 
Peter Koelblinger
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Speakers' Bureau - Amgen; Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Mitchell P. Levesque
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - Novartis; Roche
Patents, Royalties, Other Intellectual Property - EP 14 176 944.8 Levesque, MP, Widmer, D, Raaimakers, M, and Dummer, R. (2014). Means and methods for identifying a patient having a BRAF-positive cancer as a non-responder to a BRAF inhibitor and as a responder to an MAPK/ERK inhibitor. EP16203799.8 Eichh
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Corina Kaufmann
Travel, Accommodations, Expenses - Merck
 
Heiko Sülberg
Consulting or Advisory Role - NeraCare GmbH (Inst)
 
Axel Hinke
Honoraria - NeraCare GmbH; Roche Pharma AG
 
Marie-Christine Hoffmann
Employment - NeraCare GmbH
Honoraria - NeraCare GmbH
 
Georg Brunner
Employment - BioCap; NeraCare GmbH
Stock and Other Ownership Interests - NeraCare GmbH
Patents, Royalties, Other Intellectual Property - Inventor of a patent on a "Gene signature predicting clinical outcome of malignant melanoma". The patent has been transferred into NeraCare GmbH. (Inst)
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sun Pharma; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sun Pharma; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)